Combination Prophylactic Therapy with Rifampin Increases Efficacy against an Experimental Staphylococcus epidermidis Subcutaneous Implant-Related Infection

ABSTRACT The incidence of infections related to cardiac devices (such as permanent pacemakers) has been increasing out of proportion to implantation rates. As management of device infections typically requires explantation of the device, optimal prophylactic strategies are needed. Cefazolin and vancomycin are widely used as single agents for surgical prophylaxis against cardiac device-related infections. However, combination antibiotic prophylaxis may further reduce infectious complications. To model a localized subcutaneous implant-related infection, a bioluminescent strain of Staphylococcus epidermidis was inoculated onto a medical-procedure-grade titanium disc, which was placed into a subcutaneous pocket in the backs of mice. In vivo bioluminescence imaging, quantification of ex vivo CFU from the capsules and implants, variable-pressure scanning electron microscopy (VP-SEM), and neutrophil enhanced green fluorescent protein (EGFP) fluorescence in LysEGFP mice were employed to monitor the infection. This model was used to evaluate the efficacies of low- and high-dose cefazolin (50 and 200 mg/kg of body weight) and vancomycin (10 and 110 mg/kg) intravenous prophylaxis with or without rifampin (25 mg/kg). High-dose cefazolin and high-dose vancomycin treatment resulted in almost complete bacterial clearance, whereas both low-dose cefazolin and low-dose vancomycin reduced the in vivo and ex vivo bacterial burden only moderately. The addition of rifampin to low-dose cefazolin and vancomycin was highly effective in further reducing the CFU harvested from the implants. However, vancomycin-rifampin was more effective than cefazolin-rifampin in further reducing the CFU harvested from the surrounding tissue capsules. Future studies in humans will be required to determine whether the addition of rifampin has improved efficacy in preventing device-related infections in clinical practice.

[1]  A. Skanes,et al.  Cardiovascular implantable electrophysiological device-related infections: a review , 2011, Current opinion in cardiology.

[2]  K Isaaz,et al.  Antibiotic prophylaxis for permanent pacemaker implantation: a meta-analysis. , 1998, Circulation.

[3]  J. Shaw,et al.  Pharmacodynamics of Telavancin (TD-6424), a Novel Bactericidal Agent, against Gram-Positive Bacteria , 2004, Antimicrobial Agents and Chemotherapy.

[4]  C. Kirkpatrick,et al.  Protein binding of cefazolin is saturable in vivo both between and within patients. , 2007, British journal of clinical pharmacology.

[5]  G. Mandell,et al.  Killing of intraleukocytic Staphylococcus aureus by rifampin: in-vitro and in-vivo studies. , 1972, Journal of Infectious Diseases.

[6]  M. Pfeffer,et al.  Comparative Pharmacokinetics of Ceforanide (BL-S786R) and Cefazolin in Laboratory Animals and Humans , 1980, Antimicrobial Agents and Chemotherapy.

[7]  G. Forrest,et al.  Rifampin Combination Therapy for Nonmycobacterial Infections , 2010, Clinical Microbiology Reviews.

[8]  G. Archer,et al.  Alteration of staphylococcal flora in cardiac surgery patients receiving antibiotic prophylaxis. , 1983, The Journal of infectious diseases.

[9]  K. Rentsch,et al.  Efficacy of Daptomycin in Implant-Associated Infection Due to Methicillin-Resistant Staphylococcus aureus: Importance of Combination with Rifampin , 2009, Antimicrobial Agents and Chemotherapy.

[10]  G. Eliopoulos,et al.  Efficacy of Daptomycin in Experimental Endocarditis Due to Methicillin-Resistant Staphylococcusaureus , 2003, Antimicrobial Agents and Chemotherapy.

[11]  D. van Soolingen,et al.  Optimization of the rifampin dosage to improve the therapeutic efficacy in tuberculosis treatment using a murine model. , 2013, American journal of respiratory and critical care medicine.

[12]  Y. Iwakura,et al.  Protective role of IL‐1β against post‐arthroplasty Staphylococcus aureus infection , 2011, Journal of orthopaedic research : official publication of the Orthopaedic Research Society.

[13]  S. Saba,et al.  Continued Rise in Rates of Cardiovascular Implantable Electronic Device Infections in the United States: Temporal Trends and Causative Insights , 2010, Pacing and clinical electrophysiology : PACE.

[14]  David L Hayes,et al.  Permanent pacemaker and implantable cardioverter defibrillator infection: a population-based study. , 2007, Archives of internal medicine.

[15]  B. Ackerman,et al.  Vancomycin Serum Protein Binding Determination by Ultrafiltration , 1988, Drug intelligence & clinical pharmacy.

[16]  G. Bierbaum,et al.  Morphological and Genetic Differences in Two Isogenic Staphylococcus aureus Strains with Decreased Susceptibilities to Vancomycin , 2003, Antimicrobial Agents and Chemotherapy.

[17]  K. Francis,et al.  Daptomycin and Tigecycline Have Broader Effective Dose Ranges than Vancomycin as Prophylaxis against a Staphylococcus aureus Surgical Implant Infection in Mice , 2012, Antimicrobial Agents and Chemotherapy.

[18]  L. Baddour,et al.  Risk factor analysis of permanent pacemaker infection. , 2007, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[19]  D. T. Rock,et al.  Comparison of steady-state pharmacokinetics of two dosage regimens of vancomycin in normal volunteers , 1987, Antimicrobial Agents and Chemotherapy.

[20]  R. Steigbigel,et al.  Staphylococcal beta-lactamase and efficacy of beta-lactam antibiotics: in vitro and in vivo evaluation. , 1983, The Journal of infectious diseases.

[21]  S. A. D’Orio Nishioka,et al.  Efficacy of Antibiotic Prophylaxis Before the Implantation of Pacemakers and Cardioverter-Defibrillators: Results of a Large, Prospective, Randomized, Double-Blinded, Placebo-Controlled Trial , 2009, Circulation. Arrhythmia and electrophysiology.

[22]  S. Wesselingh,et al.  Clinical, Microbiological, and Economic Benefit of a Change in Antibiotic Prophylaxis for Cardiac Surgery , 2002, Infection Control & Hospital Epidemiology.

[23]  A. Hanssen,et al.  Diagnosis and management of prosthetic joint infection: clinical practice guidelines by the Infectious Diseases Society of America. , 2013, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[24]  R. Margey,et al.  Contemporary management of and outcomes from cardiac device related infections. , 2010, Europace : European pacing, arrhythmias, and cardiac electrophysiology : journal of the working groups on cardiac pacing, arrhythmias, and cardiac cellular electrophysiology of the European Society of Cardiology.

[25]  Sara E Cosgrove,et al.  Clinical practice guidelines by the infectious diseases society of america for the treatment of methicillin-resistant Staphylococcus aureus infections in adults and children. , 2011, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[26]  N. Kanuru,et al.  Implantation Success and Infection in Cardiovascular Implantable Electronic Device Procedures Utilizing an Antibacterial Envelope , 2011, Pacing and clinical electrophysiology : PACE.

[27]  E. Kantharaj,et al.  Pharmacokinetics-Pharmacodynamics of Rifampin in an Aerosol Infection Model of Tuberculosis , 2003, Antimicrobial Agents and Chemotherapy.

[28]  K. Francis,et al.  Real-Time In Vivo Bioluminescent Imaging for Evaluating the Efficacy of Antibiotics in a Rat Staphylococcus aureus Endocarditis Model , 2005, Antimicrobial Agents and Chemotherapy.

[29]  Development of real-time in vivo imaging of device-related Staphylococcus epidermidis infection in mice and influence of animal immune status on susceptibility to infection. , 2008, The Journal of infectious diseases.

[30]  P. Caravelli,et al.  Management of Cardiac Device Infections: A Retrospective Survey of a Non-Surgical Approach Combining Antibiotic Therapy with Transvenous Removal , 2006, Journal of chemotherapy.

[31]  P. Tchou,et al.  The Role of Swab and Tissue Culture in the Diagnosis of Implantable Cardiac Device Infection , 2005, Pacing and clinical electrophysiology : PACE.

[32]  A. Diacon,et al.  Why Do We Use 600 mg of Rifampicin in Tuberculosis Treatment? , 2011, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[33]  M. Rybak,et al.  Activities of High-Dose Daptomycin, Vancomycin, and Moxifloxacin Alone or in Combination with Clarithromycin or Rifampin in a Novel In Vitro Model of Staphylococcus aureus Biofilm , 2010, Antimicrobial Agents and Chemotherapy.

[34]  L. Baddour,et al.  Cardiac device infections: getting to the heart of the matter , 2006, Current opinion in infectious diseases.

[35]  K. Krause,et al.  Efficacy of telavancin in a murine model of bacteraemia induced by methicillin-resistant Staphylococcus aureus. , 2006, The Journal of antimicrobial chemotherapy.

[36]  L. Frontali,et al.  Effect of Rifamycin on Protein Synthesis , 1965, Nature.

[37]  B. Rice,et al.  Monitoring Bacterial Burden, Inflammation and Bone Damage Longitudinally Using Optical and μCT Imaging in an Orthopaedic Implant Infection in Mice , 2012, PloS one.

[38]  G. Mandell,et al.  Treatment of experimental staphylococcal infections: effect of rifampin alone and in combination on development of rifampin resistance , 1980, Antimicrobial Agents and Chemotherapy.

[39]  T. Graf,et al.  Insertion of enhanced green fluorescent protein into the lysozyme gene creates mice with green fluorescent granulocytes and macrophages. , 2000, Blood.

[40]  K. Fuursted,et al.  Activities of vancomycin and teicoplanin against penicillin-resistant pneumococci in vitro and in vivo and correlation to pharmacokinetic parameters in the mouse peritonitis model , 1997, Antimicrobial agents and chemotherapy.

[41]  K. Francis,et al.  Mouse model of chronic post‐arthroplasty infection: Noninvasive in vivo bioluminescence imaging to monitor bacterial burden for long‐term study , 2012, Journal of orthopaedic research : official publication of the Orthopaedic Research Society.

[42]  G. Mandell,et al.  Killing of Intraleukocytie Staphylococcus aureus by Rifampin: In-Vitro and In-Vivo Studies , 1972 .

[43]  C. Arrecubieta,et al.  Role of biofilm in Staphylococcus aureus and Staphylococcus epidermidis ventricular assist device driveline infections. , 2011, The Journal of thoracic and cardiovascular surgery.

[44]  G. Trevi,et al.  Bacteriology of infected extracted pacemaker and ICD leads , 2009, Journal of cardiovascular medicine.

[45]  H. Mattie,et al.  Cefazolin and cephradine: relationship between antibacterial activity in vitro and in mice experimentally infected with Escherichia coli. , 1978, The Journal of infectious diseases.

[46]  A. Kolker,et al.  Salvage of Exposed Implantable Cardiac Electrical Devices and Lead Systems With Pocket Change and Local Flap Coverage , 2007, Annals of plastic surgery.

[47]  Arkady Mustaev,et al.  Structural Mechanism for Rifampicin Inhibition of Bacterial RNA Polymerase , 2001, Cell.

[48]  M. Lobo,et al.  Treatment of Experimental Staphylococcal Infection with Rifampin , 1972, Antimicrobial Agents and Chemotherapy.

[49]  G. Finerman,et al.  A Mouse Model of Post-Arthroplasty Staphylococcus aureus Joint Infection to Evaluate In Vivo the Efficacy of Antimicrobial Implant Coatings , 2010, PloS one.

[50]  P. Welling,et al.  Pharmacology of cefazolin and other cephalosporins in patients with renal insufficiency. , 1973, The Journal of infectious diseases.

[51]  Michael C. Mosier,et al.  Antibiotics and Antiseptics to Prevent Infection in Cardiac Rhythm Management Device Implantation Surgery , 2012, Pacing and clinical electrophysiology : PACE.

[52]  D. Mack,et al.  Parallel induction by glucose of adherence and a polysaccharide antigen specific for plastic-adherent Staphylococcus epidermidis: evidence for functional relation to intercellular adhesion , 1992, Infection and immunity.

[53]  K. Bush,et al.  In Vivo Activity of Ceftobiprole in Murine Skin Infections Due to Staphylococcus aureus and Pseudomonas aeruginosa , 2009, Antimicrobial Agents and Chemotherapy.

[54]  L. Miller,et al.  Adjunctive use of rifampin for the treatment of Staphylococcus aureus infections: a systematic review of the literature. , 2008, Archives of internal medicine.

[55]  R. Darouiche,et al.  Treatment of infections associated with surgical implants. , 2004, The New England journal of medicine.

[56]  J. Jenkins,et al.  Plasma and Tissue Pharmacokinetics of Cefazolin in Patients Undergoing Elective and Semielective Abdominal Aortic Aneurysm Open Repair Surgery , 2011, Antimicrobial Agents and Chemotherapy.

[57]  K. Krause,et al.  Efficacy of Telavancin (TD-6424), a Rapidly Bactericidal Lipoglycopeptide with Multiple Mechanisms of Action, in a Murine Model of Pneumonia Induced by Methicillin-Resistant Staphylococcus aureus , 2005, Antimicrobial Agents and Chemotherapy.

[58]  R. Kobza,et al.  Bacterial Colonization and Infection of Electrophysiological Cardiac Devices Detected With Sonication and Swab Culture , 2010, Circulation.

[59]  S. Aaron,et al.  Multiple Combination Bactericidal Testing of Staphylococcal Biofilms from Implant-Associated Infections , 2006, Antimicrobial Agents and Chemotherapy.

[60]  Walter R Wilson,et al.  Update on cardiovascular implantable electronic device infections and their management: a scientific statement from the American Heart Association. , 2010, Circulation.

[61]  Daniel R. Frisch,et al.  16-year trends in the infection burden for pacemakers and implantable cardioverter-defibrillators in the United States 1993 to 2008. , 2011, Journal of the American College of Cardiology.

[62]  David L Hayes,et al.  Management and outcome of permanent pacemaker and implantable cardioverter-defibrillator infections. , 2007, Journal of the American College of Cardiology.

[63]  R. Ghiselli,et al.  Daptomycin and rifampin alone and in combination prevent vascular graft biofilm formation and emergence of antibiotic resistance in a subcutaneous rat pouch model of staphylococcal infection. , 2010, European journal of vascular and endovascular surgery : the official journal of the European Society for Vascular Surgery.

[64]  M. Chung,et al.  Cardiovascular Implantable Electronic Device Replacement Infections and Prevention: Results from the REPLACE Registry , 2012, Pacing and clinical electrophysiology : PACE.

[65]  S. Chambers,et al.  Diagnosis and management of staphylococcal infections of pacemakers and cardiac defibrillators , 2005, Internal medicine journal.

[66]  R. Steigbigel,et al.  Staphylococcal β-Lactamase and Efficacy of β-Lactam Antibiotics: In Vitro and in Vivo Evaluation , 1983 .

[67]  D. Nicolau,et al.  Comparative Efficacies of Human Simulated Exposures of Telavancin and Vancomycin against Methicillin-Resistant Staphylococcus aureus with a Range of Vancomycin MICs in a Murine Pneumonia Model , 2010, Antimicrobial Agents and Chemotherapy.

[68]  I. Raad,et al.  Comparative Activities of Daptomycin, Linezolid, and Tigecycline against Catheter-Related Methicillin-Resistant Staphylococcus Bacteremic Isolates Embedded in Biofilm , 2007, Antimicrobial Agents and Chemotherapy.